Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial

Immune modulation: translating the benefits The immune system modulating drug sargramostim shows promising results in a small clinical trial with Parkinson’s disease (PD) patients. Previous studies have shown that sargramostim increases the number of regulatory T cells, attenuates immune responses,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Howard E. Gendelman, Yuning Zhang, Pamela Santamaria, Katherine E. Olson, Charles R. Schutt, Danish Bhatti, Bhagya Laxmi Dyavar Shetty, Yaman Lu, Katherine A. Estes, David G. Standaert, Elizabeth Heinrichs-Graham, LuAnn Larson, Jane L. Meza, Matthew Follett, Erica Forsberg, Gary Siuzdak, Tony W. Wilson, Carolyn Peterson, R. Lee Mosley
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ee69bcd53fbd419bb5945c4e0f267aba
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ee69bcd53fbd419bb5945c4e0f267aba
record_format	dspace
spelling	oai:doaj.org-article:ee69bcd53fbd419bb5945c4e0f267aba2021-12-02T12:33:37ZEvaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial10.1038/s41531-017-0013-52373-8057https://doaj.org/article/ee69bcd53fbd419bb5945c4e0f267aba2017-03-01T00:00:00Zhttps://doi.org/10.1038/s41531-017-0013-5https://doaj.org/toc/2373-8057Immune modulation: translating the benefits The immune system modulating drug sargramostim shows promising results in a small clinical trial with Parkinson’s disease (PD) patients. Previous studies have shown that sargramostim increases the number of regulatory T cells, attenuates immune responses, and confers neuroprotection in animal models of neurodegenerative disease. To determine whether these findings translate to humans, Howard E. Gendelman at the University of Nebraska Medical Center, USA, and colleagues examined the effects of sargramostim in 20 patients with PD. Despite the high number of mild to moderate reported adverse events, the drug was generally well tolerated and led to an increase in regulatory T cell number and activity. Moreover, preliminary assessments after 6 and 8 weeks of treatment suggested an overall improvement in the motor skills of patients that received the drug compared with those that received a placebo.Howard E. GendelmanYuning ZhangPamela SantamariaKatherine E. OlsonCharles R. SchuttDanish BhattiBhagya Laxmi Dyavar ShettyYaman LuKatherine A. EstesDavid G. StandaertElizabeth Heinrichs-GrahamLuAnn LarsonJane L. MezaMatthew FollettErica ForsbergGary SiuzdakTony W. WilsonCarolyn PetersonR. Lee MosleyNature PortfolioarticleNeurology. Diseases of the nervous systemRC346-429ENnpj Parkinson's Disease, Vol 3, Iss 1, Pp 1-12 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurology. Diseases of the nervous system RC346-429 Howard E. Gendelman Yuning Zhang Pamela Santamaria Katherine E. Olson Charles R. Schutt Danish Bhatti Bhagya Laxmi Dyavar Shetty Yaman Lu Katherine A. Estes David G. Standaert Elizabeth Heinrichs-Graham LuAnn Larson Jane L. Meza Matthew Follett Erica Forsberg Gary Siuzdak Tony W. Wilson Carolyn Peterson R. Lee Mosley Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial
description	Immune modulation: translating the benefits The immune system modulating drug sargramostim shows promising results in a small clinical trial with Parkinson’s disease (PD) patients. Previous studies have shown that sargramostim increases the number of regulatory T cells, attenuates immune responses, and confers neuroprotection in animal models of neurodegenerative disease. To determine whether these findings translate to humans, Howard E. Gendelman at the University of Nebraska Medical Center, USA, and colleagues examined the effects of sargramostim in 20 patients with PD. Despite the high number of mild to moderate reported adverse events, the drug was generally well tolerated and led to an increase in regulatory T cell number and activity. Moreover, preliminary assessments after 6 and 8 weeks of treatment suggested an overall improvement in the motor skills of patients that received the drug compared with those that received a placebo.
format	article
author	Howard E. Gendelman Yuning Zhang Pamela Santamaria Katherine E. Olson Charles R. Schutt Danish Bhatti Bhagya Laxmi Dyavar Shetty Yaman Lu Katherine A. Estes David G. Standaert Elizabeth Heinrichs-Graham LuAnn Larson Jane L. Meza Matthew Follett Erica Forsberg Gary Siuzdak Tony W. Wilson Carolyn Peterson R. Lee Mosley
author_facet	Howard E. Gendelman Yuning Zhang Pamela Santamaria Katherine E. Olson Charles R. Schutt Danish Bhatti Bhagya Laxmi Dyavar Shetty Yaman Lu Katherine A. Estes David G. Standaert Elizabeth Heinrichs-Graham LuAnn Larson Jane L. Meza Matthew Follett Erica Forsberg Gary Siuzdak Tony W. Wilson Carolyn Peterson R. Lee Mosley
author_sort	Howard E. Gendelman
title	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial
title_short	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial
title_full	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial
title_fullStr	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial
title_full_unstemmed	Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial
title_sort	evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical parkinson’s disease trial
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/ee69bcd53fbd419bb5945c4e0f267aba
work_keys_str_mv	AT howardegendelman evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT yuningzhang evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT pamelasantamaria evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT katherineeolson evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT charlesrschutt evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT danishbhatti evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT bhagyalaxmidyavarshetty evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT yamanlu evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT katherineaestes evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT davidgstandaert evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT elizabethheinrichsgraham evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT luannlarson evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT janelmeza evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT matthewfollett evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT ericaforsberg evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT garysiuzdak evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT tonywwilson evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT carolynpeterson evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial AT rleemosley evaluationofthesafetyandimmunomodulatoryeffectsofsargramostiminarandomizeddoubleblindphase1clinicalparkinsonsdiseasetrial
_version_	1718393893746114560

Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial

Ejemplares similares